---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-051018"
form_type: "8-K"
ticker: "DMAA"
cik: "0002028614"
company_name: "Drugs Made In America Acquisition Corp."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:24:20.568899+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M

## Summary
- Extension proposal approved: 18,906,281 for, 4,892,646 against, 0 abstain.
- Combination period extended up to 12 months to April 29, 2027 with monthly deposits of ~$300k.
- Redemption of 9,440,230 shares at ~$10.52/share, removing $99,336,016.67 from trust account.
- Post-redemption shares outstanding: 24,276,913 (13,559,770 from IPO).
- Board approved initial one-month extension to May 29, 2026.

## SEC filing metadata
- accession: 0001213900-26-051018
- form_type: 8-K
- ticker: DMAA
- cik: 0002028614
- company_name: Drugs Made In America Acquisition Corp.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/0001213900-26-051018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/ea0288774-8k_drugs.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-051018
- JSON: https://secwatch.observer/filing/0001213900-26-051018.json
- Plain text: https://secwatch.observer/filing/0001213900-26-051018.txt

## Source-grounded claims
- claim_id: 0a4526655bc60d865fa1873e37632a7619ea0187
  claim: Drugs Made In America Acquisition Corp.: Amended charter to extend business combination deadline from April 29, 2026 to April 29, 2027, with up to twelve monthly extensions subject to sponsor deposit (effective 2026-04-27).
  evidence_excerpt: to amend the Company’s Second Amended and Restated Memorandum and Articles of Association (the “ Existing Charter ”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “ Extension Amendment ”) which reflects the extension of the date by which the Company must consummate a business combination (the “ Combination Period ”) up to twelve (12) times from April 29, 2026 (the “ Termination Date ”) to April 29, 2027, each by an additional one (1) month
  evidence_url: https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/0001213900-26-051018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.